Ruxolitinib, a JAK1 and JAK2 kinase inhibitor approved by the FDA for the treatment of myelofibrosis, showed a potential to attenuate severe skin changes in a mouse model of SLE [146]. Here, JAK1 is linked to systemic lupus erythematosus.